#Israel #Rehovot #Nir Nimrodi #Evogene #Sarit Firon

Evogene Appoints Nir Nimrodi as Chairperson of the Board

Evogene Ltd., a prominent company in computational biology, has announced the appointment of Nir Nimrodi as the new Chairperson of the Board, effective March 5, 2025. This decision marks a significant transition for the company as it shifts leadership from Sarit Firon, who has held the position since August 2021 and will continue as a Board member.

Mr. Nimrodi's extensive background in the life sciences sector makes him an ideal candidate to lead Evogene during an important phase of its development. With over two decades of experience acquired at both startups and large, established organizations within the pharmaceutical and biotechnology fields, he brings a wealth of knowledge that is expected to greatly benefit Evogene's ongoing projects and its strategic direction.

Ofer Haviv, the President and CEO of Evogene, expressed his enthusiasm regarding Nimrodi's new role. "On behalf of Evogene, I am pleased to welcome Nir Nimrodi as the new Chairperson of the Board. His engagement with Evogene since 2020 has shown his commitment to our mission. I look forward to working closely with him to navigate our goals moving forward." Furthermore, Haviv expressed gratitude towards Firon's contributions, highlighting the solid foundation she provided during her tenure.

Nir Nimrodi himself shared his excitement about the opportunities ahead for Evogene, stating, "Several assets within our company have great potential to create significant value for Evogene and its shareholders. I am committed to focusing on strategies that will unlock this value starting this year."

Evogene is well-positioned for innovation, having utilized cutting-edge computational methods to drive its product development for over 20 years. With the integration of AI technologies—an area where the company has emerged as a leader—Nimrodi aims to further enhance the drug discovery process and increase the value offered to stakeholders.

As part of the leadership restructure, Ofer Haviv is also joining the Board as a member while retaining his position as President and CEO. This strategic move is anticipated to reinforce the company's governance and operational efficacy as Evogene works towards achieving its ambitious milestones across various subsidiaries and programs.

About Evogene Ltd.

Evogene Ltd. is at the forefront of utilizing big data and artificial intelligence to revolutionize the development of life-science based products. Their approach aims to enhance the success rate of product development while minimizing costs and time. Evogene is distinguished by its three innovative tech engines:
1. MicroBoost AI: This engine focuses on discovering products derived from microbes.
2. ChemPass AI: Here, the emphasis is on small molecules for product development.
3. GeneRator AI: This engine centers around genetic elements in product discovery.

Through partnerships and collaborations, Evogene aims to leverage these unique tech engines to create groundbreaking products across various sectors, including agriculture and healthcare.

Subsidiaries and Development Focus:

• - Casterra Ag Ltd.: Specializing in developing high-yield castor seed varieties.
• - Lavie Bio Ltd.: Concentrated on advancing microbiome-based agricultural solutions.
• - AgPlenus Ltd.: Focused on next-generation agricultural chemicals for sustainable crop protection.
• - Biomica Ltd.: Dedicated to developing microbiome-based therapeutics.

In summary, the appointment of Nir Nimrodi as Chairperson is viewed as a promising opportunity for Evogene to build on its achievements and continue its path towards impactful innovations in life sciences. The journey ahead looks promising, as the company is clearly poised for continued growth and leadership in its field.